Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00p -1.87% 52.50p 51.00p 54.00p 53.50p 52.50p 53.50p 107,245 12:22:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.6 -8.9 -10.1 - 75.33

Angle Share Discussion Threads

Showing 48701 to 48725 of 48725 messages
Chat Pages: 1949  1948  1947  1946  1945  1944  1943  1942  1941  1940  1939  1938  Older
DateSubjectAuthorDiscuss
17/1/2019
19:25
Hi Buywell you may find slide 9 of this presentation useful as it lists out some of the companies in the CTC landscape and shows their capabilities compared to Parsortix. Although metacell isn't mentioned it falls into the membrane category and suffers from the same harvesting problems. hTTps://angleplc.com/wp-content/uploads/ANGLE-Presentation-Biotech-Showcase-San-Francisco-11jan16.pdf
miavoce
17/1/2019
16:08
Metacell have been on here before, as usual people have the memory of a sieve, or should that be a CTC filtering device. AGL's response when someone raised the query 2 or 3 years back was that few if any of the various instiutions they dealt with had ever even heard of Metacell and no-one they knew was using their tech. Then there is the fact that the long and tortuous route to FDA Approval is very expensive as AGL have discovered the hard way.
banshee
17/1/2019
15:57
Buywell, the “Publications” page lacks a certain something if you ask me. hTTP://www.metacell.cz/publications.html
chippyfriday
17/1/2019
07:53
Seems like it took 5 mins to put that website together...
zeus19
17/1/2019
01:53
You won't see this other CTC supplier/testing provider then hTTp://www.metacell.cz/technology.html
buywell3
16/1/2019
22:22
Anaway he is now my second filtered person on this board.
lairddavid
16/1/2019
22:05
That is certainly more likely....
miavoce
16/1/2019
20:24
Trick cyclist?
semper vigilans
16/1/2019
20:10
I suspect that Buywell probably isn't an oncologist
miavoce
16/1/2019
19:33
Buywell, I think even Bones might consider blocking you after that piece of intelligent rational.
drums1
16/1/2019
19:17
Buywell,Your missing the point,These days it is rarely the primary cancer that kills it is secondary cancers that creep up on you years later. These are spread by CTC's and regular checks through a simple blood test would help diagnose this very early and may enable a higher survival rate. That's why AGL's first FDA application is metastatic Breast Cancer. So every patient that has had a breast removed should have a parsortix blood test every so often. That's exactly the point.
jelenko
16/1/2019
19:07
Bloody hell buywell, are you seriously telling us that no-one that's been diagnosed with cancer has ever survived more than 18 months?
arthur_lame_stocks
16/1/2019
19:01
Having a breast removed is the best way to stay alive ... ask a consultant Once someone has a tumor ... then they have cancer (unless it is benign) CTC's were first talked about over 100 years ago ... in my view they come too late in the day regarding cancer , once the tumor is there you have the disease . Genetic testing is going to happen to see if one has the bad genes BEFORE cancer kicks in Cancer drugs make the most money for Pharmas at $100,000 a year treatment but they don't cure it. They lengthen your survival time perhaps to 18 months or a bit more , however quality of life reduces as the time goes by. The last 3 to 4 months are terrible and morphine derivatives are used in the latter stages in many/most cases.
buywell3
16/1/2019
15:57
SK, I don't know whether the current trial would be sufficient for FDA approval for HER2 status testing - I'm not even sure what the requirements are when it comes to individual assays. In terms of the size of the market, I haven't checked but every single new case of breast cancer requires HER2 testing, it's the most common cancer in women with about 2 million new cases last year. The problem is that HER2 status can change but obviously women can't keep having tissue biopsies. The chance to regularly test HER2 status via a simple blood test will help to ensure that women continue to receive the appropriate treatment for their HER2 status and changes can be made immediately rather than waiting until the cancer has progressed and another tissue biopsy is carried out. It's potentially a huge market but above all an important development for women that should improve survival and bring peace of mind for the patient. I think this is where the market for liquid biopsy lies - ie. repeat testing rather than with new cases. I assume that Abbott will be very interested indeed if the current breast cancer trial shows that CTCs can be used successfully for HER2 testing.
bermudashorts
16/1/2019
10:53
Buywell, what you should be asking is why these three global companies have chosen to partner with Angle and use Parsortix. During the year, three partnerships were signed. A co-marketing agreement was signed with world-leading molecular testing company QIAGEN. QIAGEN employs 4,600 people in over 35 countries and has more than 500,000 customers with annual revenues exceeding US $1.3 billion. The first area of focus is to couple the Parsortix system with QIAGEN's downstream technologies for use in prostate and breast cancer research. Protocols are currently being developed and optimised to allow sales into QIAGEN's established customer base. A collaborative research project was signed with Philips, a global leader in health technology, to develop liquid biopsy solutions as part of a four year European Union research grant funded programme worth €6.3 million, of which £0.4 million will flow to ANGLE. Philips has selected the Parsortix system as the only system to be used for harvesting CTCs within the programme. Breast and rectal cancers are being targeted. An agreement was signed with global healthcare company Abbott in which Abbott will supply ANGLE with its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 FDA study for FISH (fluorescence in situ hybridization) analysis of circulating tumor cells (CTCs) in the form of a research grant. The objective of this end-point is to demonstrate that harvested CTCs can be subjected to FISH analysis to determine their HER-2 status. Assuming this is successful, we hope to be able to work with Abbott to extend PathVysion use into routine blood test analysis as an important downstream application of the Parsortix system in breast cancer. Abbott is the global market leader for FISH testing in solid tissue biopsies, a market estimated to be worth $0.5 billion per annum in 2016 (source: Grand View Research). A positive result in this clinical study would demonstrate the potential for Abbott to offer a Parsortix-based product for HER-2 analysis from a routine blood test.
chippyfriday
16/1/2019
10:40
SK, the title of your thread is "ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET" Have you given up on this scenario? All your posts referring to sales forecasts and future dilution seem to relate to AGL ploughing a lone furrow.
thailand
16/1/2019
10:36
At a glance the Market was $75 million, but things have moved on with market sizes estimate at 145 -158 million in 2017-2018. Some figures and links relating below, wasn't willing to $5,400.00 for the full reports so headline figures, and some interesting comments on NIPT. The Breast Cancer Liquid Biopsy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Breast Cancer Liquid Biopsy market size to maintain the average annual growth rate of 23.12% from 77.9 million $ in 2014 to 145.4 million $ in 2017,"http://m.digitaljournal.com/pr/3961623According to the report, global breast cancer liquid biopsy market was valued at approximately USD 151.8 million in 2017 and is expected to generate revenue of around USD 642.9 million by end of 2024, growing at a CAGR of around 22.9% between 2018 and 2024.https://globenewswire.com/news-release/2018/09/05/1565326/0/en/Breast-Cancer-Liquid-Biopsy-Market-Will-Grow-USD-642-9-Million-By-2024-Globally-Zion-Market-Research.html"The non-cancer application segment is projected to grow at the highest CAGR during the forecast period"Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications (which include reproductive health and organ transplant diagnostics). The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period. This is due to the growing application in noninvasive prenatal testing (NIPT), using cell-free DNA assays in the identification of trisomies (which includes 13, 16, and 18), gender identification, and other genetic abnormalities such as monosomy X and microdeletions. NIPT is also rapidly replacing amniocentesis in high-risk pregnancies, thus expanding its application."https://www.insightpharmareports.com/liquid-biopsy-market-by-cancer-type-circulating-biomarkers-product-end-user-global-forecast-to-2022
l0ngterm
16/1/2019
09:59
Thanks Waterloo. Shows again that I am out of date here. It would however be interesting to know what the peak market sales for HER2 might be as the peak market sales for ovarian and metastatic breast cancer appear to be very low. Also would another trial be required to make wider HER2 claims if only metastatic patients are tested, for whom we know the claimed market size.
sicilian_kan
16/1/2019
09:50
I think it's one of the outcomes of the current trial "FISH analysis, which is a form of investigation of the cancer cells used with solid tissue biopsy to help select treatment, is one of the exploratory end-points for ANGLE's FDA study in metastatic breast cancer. The objective of this end-point is to demonstrate that CTCs can be harvested from the blood of metastatic breast cancer patients using the Parsortix(TM) system and that the harvested CTCs can then be subjected to FISH analysis to determine their HER-2 status." Kathryn B Becker, PhD, Franchise Director Oncology and Companion Diagnostics, Abbott commented: "Abbott is pleased to collaborate with ANGLE in this important evaluation of PathVysion in liquid biopsy specimens. The PathVysion HER-2 DNA FISH Probe kit is reliable and accurate in tissue biopsy samples and the Parsortix system may unlock the potential for PathVysion use in a simple blood test. We look forward to the outcomes of the study and the potential opportunity to further collaborate with ANGLE in combining FISH and liquid biopsy in other areas."
waterloo01
16/1/2019
09:45
Hi Bermuda, yes the peak sales of $75m were based upon metastatic breast cancer rather than HER2 testing, but that is the one currently in trial, not HER2 testing, as far as I am aware. Of course there are other potential applications, but they will need more time and more dilution and the clinical uses for which they are currently doing trials appear quite small in terms of potential revenues. Angle would have done much better to have done a tie up earlier with a partner funding rather than to incur all the dilution to date.
sicilian_kan
16/1/2019
09:12
And don't forget that Parsortix can capture fetal cells (recently announced that a 3rd party has done this and has then used those cells for testing for genetic conditions)...we will hopefully see a deal with a 3rd party who wishes to take this forward and commercialise it.
miavoce
16/1/2019
08:31
I don’t recall the sale price for Cellsearch being disclosed either. Though someone may put me right on this.
semper vigilans
16/1/2019
08:31
Miavoce, well put but not sure that particular poster will be moved, regardless.
waterloo01
16/1/2019
08:26
Buywell your argument that J&J offloaded CellSearch because they didn't think there was a future for CTC's does not stack up. Cellsearch's only capability is to capture SOME types of CTC (EpCAM positive), which allows them to be counted. Also when catching the CTC's it kills them. Think of it as a net that can only catch certain types of fish, and in the process of catching them kills them, and having caught the fish in the net all you can then do is count them, you can't get them out and actually do anything useful with them. Parsortix on the other hand can capture ALL types of CTC, including clusters, and enables those CTC's to them be harvested, alive, for further analysis / culture / drug testing etc. Think of it as a net that captures all fish and then allows those fish to be removed from the net, then examined, used for breeding, etc. See the difference ? Parsortix is enabling liquid biopsy, one of the hottest topics in oncology, to become a reality, and month after month new discoveries are being made about what CTC's can be used for in diagnostics, drug selection etc. Why did J&J offload Cellsearch - probably because it is so limited in its capability its potential market is very small.
miavoce
16/1/2019
08:14
I know Toffee, but I would rather see what was being said, however inaccurate, so it can be put right if wrong. If you kept annoying someone in a pub in a similar way, you would get a smack in the mouth: a reasonable edict - make sure what you write, you would be prepared to say in public.
semper vigilans
Chat Pages: 1949  1948  1947  1946  1945  1944  1943  1942  1941  1940  1939  1938  Older
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190118 13:21:18